Urticaria - A Pipeline Analysis Report

This pipeline analysis report provides detailed insights into the clinical trials landscape of the drug development for urticaria including molecules at pre-clinical, Phase I, Phase II, and Phase III discovery stages. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration, by territory, therapeutic modality, and target.

Overview of the drug development pipeline for urticaria  

Urticaria is a skin disorder, popularly termed as hives. This disorder surfaces in the form of raised and itchy rashes on the skin. These rashes may cover an area of a few millimeters to several centimeters. The most common hives causing foods are nuts, chocolates, fish, tomatoes, eggs, fresh berries, and milk. In addition to certain foods, medications, infections, insect bites, and internal diseases may also be responsible. Technavio’s market research analysts have predicted that with the growing incidence of urticaria among the population, second-generation antihistamines are the primary pharmacological treatment. Also, the ineffectiveness of antihistamines drives the need for the addition of Montelukast aids in controlling the spread of urticaria.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the phase II drug development stage. Our market research analysts have also identified that this is followed by numerous molecules in Phase I and Phase II drug development stage. The pipeline landscape in the pipeline analysis report also mentions the percentage of drug development molecules that are in the pre-clinical stage. 

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug development molecules for the treatment of urticaria. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are:

• GlaxoSmithKline
• Glenmark
• Novartis

Therapeutic assessment of the drug development pipeline for urticaria by route of administration

• Subcutaneous
• Oral
• Intravenous
• Topical

The subcutaneous route of administration (ROA) involves the administration of drug substances directly into the subcutis. It has been observed that the majority of total therapeutics for urticaria are being developed for subcutaneous administration.

Therapeutic assessment of the drug development pipeline for urticaria by therapy

• Monotherapy

According to this pipeline analysis report, a majority of the molecules that are currently in the drug development pipeline for urticaria are being used through monotherapy. This therapy technique involves the use of a single drug to treat a particular disorder. 

Key questions answered in the report include

• What are the drug development molecules in the various development stages for urticaria?
• What are the companies that are currently involved in the development of drug development molecules for urticaria?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.